Fresenius SE & Co. KGaA (FRE) - Net Assets
Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) has net assets worth €19.27 Billion EUR (≈ $22.53 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€42.46 Billion ≈ $49.64 Billion USD) and total liabilities (€23.19 Billion ≈ $27.11 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FRE capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.27 Billion |
| % of Total Assets | 45.38% |
| Annual Growth Rate | 8.5% |
| 5-Year Change | -22.03% |
| 10-Year Change | 7.07% |
| Growth Volatility | 30.53 |
Fresenius SE & Co. KGaA - Net Assets Trend (2002–2024)
This chart illustrates how Fresenius SE & Co. KGaA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Fresenius SE & Co. KGaA (FRE) market capitalisation.
Annual Net Assets for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual net assets of Fresenius SE & Co. KGaA from 2002 to 2024. Also explore Fresenius SE & Co. KGaA annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
+3.25% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
-39.01% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
+10.00% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
+12.55% |
| 2020-12-31 | €26.02 Billion ≈ $30.42 Billion |
-2.10% |
| 2019-12-31 | €26.58 Billion ≈ $31.07 Billion |
+6.29% |
| 2018-12-31 | €25.01 Billion ≈ $29.24 Billion |
+15.14% |
| 2017-12-31 | €21.72 Billion ≈ $25.39 Billion |
+0.54% |
| 2016-12-31 | €21.60 Billion ≈ $25.26 Billion |
+14.01% |
| 2015-12-31 | €18.95 Billion ≈ $22.15 Billion |
+17.24% |
| 2014-12-31 | €16.16 Billion ≈ $18.90 Billion |
+17.71% |
| 2013-12-31 | €13.73 Billion ≈ $16.05 Billion |
+4.38% |
| 2012-12-31 | €13.16 Billion ≈ $15.38 Billion |
+24.38% |
| 2011-12-31 | €10.58 Billion ≈ $12.37 Billion |
+19.60% |
| 2010-12-31 | €8.84 Billion ≈ $10.34 Billion |
+15.58% |
| 2009-12-31 | €7.65 Billion ≈ $8.95 Billion |
+10.21% |
| 2008-12-31 | €6.94 Billion ≈ $8.12 Billion |
+108.00% |
| 2007-12-31 | €3.34 Billion ≈ $3.90 Billion |
+7.61% |
| 2006-12-31 | €3.10 Billion ≈ $3.63 Billion |
+11.74% |
| 2005-12-31 | €2.78 Billion ≈ $3.25 Billion |
+73.18% |
| 2004-12-31 | €1.60 Billion ≈ $1.87 Billion |
-50.12% |
| 2003-12-31 | €3.21 Billion ≈ $3.76 Billion |
-4.60% |
| 2002-12-31 | €3.37 Billion ≈ $3.94 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fresenius SE & Co. KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1403800000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €14.04 Billion | 71.84% |
| Common Stock | €563.00 Million | 2.88% |
| Other Comprehensive Income | €626.00 Million | 3.20% |
| Other Components | €4.32 Billion | 22.08% |
| Total Equity | €19.54 Billion | 100.00% |
Fresenius SE & Co. KGaA Competitors by Market Cap
The table below lists competitors of Fresenius SE & Co. KGaA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Life Insurance Company Limited
F:CHL
|
$28.51 Billion |
|
DexCom Inc
NASDAQ:DXCM
|
$28.58 Billion |
|
Capitec Bank Holdings Ltd
JSE:CPI
|
$28.66 Billion |
|
Allegheny Technologies Incorporated
NYSE:ATI
|
$28.68 Billion |
|
Heidelberg Materials AG
XETRA:HEI
|
$28.48 Billion |
|
TDK Corporation
F:TDKA
|
$28.47 Billion |
|
Talanx AG
XETRA:TLX
|
$28.46 Billion |
|
Koninklijke Ahold Delhaize NV
AS:AD
|
$28.36 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fresenius SE & Co. KGaA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,999,000,000 to 19,542,000,000, a change of 543,000,000 (2.9%).
- Net income of 471,000,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 608,000,000.
- Other factors decreased equity by 536,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €471.00 Million | +2.41% |
| Other Comprehensive Income | €608.00 Million | +3.11% |
| Other Changes | €-536.00 Million | -2.74% |
| Total Change | €- | 2.86% |
Book Value vs Market Value Analysis
This analysis compares Fresenius SE & Co. KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €-1.26 | €43.30 | x |
| 2003-12-31 | €-1.15 | €43.30 | x |
| 2004-12-31 | €12.98 | €43.30 | x |
| 2005-12-31 | €21.88 | €43.30 | x |
| 2006-12-31 | €6.68 | €43.30 | x |
| 2007-12-31 | €7.10 | €43.30 | x |
| 2008-12-31 | €8.19 | €43.30 | x |
| 2009-12-31 | €8.78 | €43.30 | x |
| 2010-12-31 | €10.15 | €43.30 | x |
| 2011-12-31 | €12.09 | €43.30 | x |
| 2012-12-31 | €14.55 | €43.30 | x |
| 2013-12-31 | €15.16 | €43.30 | x |
| 2014-12-31 | €17.12 | €43.30 | x |
| 2015-12-31 | €19.91 | €43.30 | x |
| 2016-12-31 | €22.69 | €43.30 | x |
| 2017-12-31 | €24.46 | €43.30 | x |
| 2018-12-31 | €27.60 | €43.30 | x |
| 2019-12-31 | €30.10 | €43.30 | x |
| 2020-12-31 | €30.39 | €43.30 | x |
| 2021-12-31 | €34.04 | €43.30 | x |
| 2022-12-31 | €36.37 | €43.30 | x |
| 2023-12-31 | €33.73 | €43.30 | x |
| 2024-12-31 | €34.70 | €43.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fresenius SE & Co. KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.16%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.23x
- Recent ROE (2.41%) is below the historical average (10.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 1.79% | 0.84x | 0.00x | €149.50 Million |
| 2003 | 0.00% | 1.63% | 0.85x | 0.00x | €129.20 Million |
| 2004 | 10.48% | 2.31% | 0.89x | 5.11x | €7.70 Million |
| 2005 | 8.00% | 2.81% | 0.68x | 4.18x | €-55.60 Million |
| 2006 | 10.64% | 3.06% | 0.72x | 4.84x | €19.80 Million |
| 2007 | 12.28% | 3.61% | 0.74x | 4.59x | €76.20 Million |
| 2008 | 6.91% | 2.19% | 0.60x | 5.25x | €-121.00 Million |
| 2009 | 23.21% | 7.00% | 0.68x | 4.89x | €564.00 Million |
| 2010 | 24.27% | 7.54% | 0.68x | 4.75x | €708.50 Million |
| 2011 | 22.24% | 8.04% | 0.63x | 4.41x | €730.90 Million |
| 2012 | 12.13% | 4.80% | 0.63x | 4.02x | €162.70 Million |
| 2013 | 12.34% | 4.97% | 0.62x | 4.00x | €191.50 Million |
| 2014 | 11.43% | 4.59% | 0.58x | 4.27x | €133.50 Million |
| 2015 | 12.42% | 4.92% | 0.64x | 3.95x | €264.50 Million |
| 2016 | 12.74% | 5.48% | 0.63x | 3.71x | €342.70 Million |
| 2017 | 13.28% | 5.35% | 0.64x | 3.89x | €447.90 Million |
| 2018 | 13.15% | 6.05% | 0.59x | 3.68x | €485.90 Million |
| 2019 | 11.22% | 5.32% | 0.53x | 3.99x | €205.20 Million |
| 2020 | 10.07% | 4.71% | 0.54x | 3.93x | €12.10 Million |
| 2021 | 9.57% | 4.85% | 0.52x | 3.79x | €-81.80 Million |
| 2022 | 6.72% | 3.36% | 0.53x | 3.74x | €-669.50 Million |
| 2023 | -3.13% | -2.66% | 0.49x | 2.38x | €-2.49 Billion |
| 2024 | 2.41% | 2.16% | 0.50x | 2.23x | €-1.48 Billion |
Industry Comparison
This section compares Fresenius SE & Co. KGaA's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,014,753,262
- Average return on equity (ROE) among peers: -87.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fresenius SE & Co. KGaA (FRE) | €19.27 Billion | 0.00% | 1.20x | $28.51 Billion |
| China Resources Medical Holdings Company Limited (1PH) | $5.36 Billion | -28.13% | 0.20x | $354.05 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $33.63 Million | -111.31% | 15.67x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $8.75 Billion | 3.88% | 0.47x | $561.64 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.27 Billion | 3.47% | 0.87x | $20.11 Million |
| HYGEIA HC HLDGS DL-00001 (50I) | $6.25 Billion | 10.92% | 0.72x | $11.92K |
| COMPASS PATHW SP.ADR (5Y6) | $-52.85 Million | 0.00% | 0.00x | $657.30 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $17.62 Billion | 6.90% | 0.18x | $53.31K |
| Eifelhöhen-Klinik AG (EIF) | $16.98 Million | -0.92% | 1.81x | $10.05 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $10.89 Billion | 10.85% | 1.35x | $10.91 Billion |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more